抗生物質耐性の世界市場規模、シェア、成長分析、薬剤クラス別、病原体別、疾患別-産業予測、2024～2031年

世界の抗生物質耐性市場規模は2022年に89億8,000万米ドルと評価され、2023年の101億6,000万米ドルから2031年には273億9,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは13.19％で成長する展望です。

抗生物質耐性の世界市場は、抗生物質耐性菌がもたらす課題の深刻化に牽引され、世界的に著しい拡大が見られます。当レポートでは、抗生物質耐性市場のバリューチェーンを詳細に分析し、予測期間中に競合を強化するための競合考察をメーカーに記載しています。抗生物質耐性の蔓延は、感染症に対する従来の治療法の有効性を危うくしており、その主要原因は抗生物質の誤用や乱用の横行です。医療環境における不十分な感染予防対策が耐性株の蔓延をさらに悪化させ、開発中の新規抗生物質の憂慮すべき不足がこれに拍車をかけています。この危機の緊急性を認識し、政府、医療機関、製薬企業は、様々な手段で抗生物質耐性と闘うべく、ますます結束を強めています。官民パートナーシップの奨励は抗生物質の技術革新を刺激することを目的とし、抗生物質スチュワードシップ・プログラムの採用は抗生物質の使用を最適化し、耐性を抑制する上で勢いを増しています。同時に、医療従事者や一般市民を対象とした教育キャンペーンにより、処方方法の改善と抗生物質耐性に対する意識の醸成が図られています。ゲノミクスやプロテオミクスのような技術的進歩を活用することは、耐性メカニズムを解明し、新たな治療アプローチを考案する上で有望です。ファージ療法や免疫療法のような新たな選択肢は、抗生物質耐性に対抗する潜在的な解決策を記載しています。抗生物質耐性の状況は課題と機会の両方を提示しているため、エスカレートする脅威を緩和し、将来の効果的な細菌感染症治療を守るためには、協調的な取り組みが不可欠です。

目次

エグゼクティブサマリー

• 市場概要
• 繁栄と衰退

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模の推定
• 市場の危機と限界

親市場の分析

• 市場概要
• 市場規模
• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題

主要市場の考察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 貿易分析
• スタートアップ分析
• 原材料の分析
• イノベーションマトリクス
• パイプライン製品の分析
• マクロ経済指標
• 主要投資の分析
• 主要成功要因
• 競合の程度

市場力学と展望

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• 規制情勢
• ポーターの分析
• 将来の混乱についての特別な考察

抗生物質耐性の世界市場：薬剤クラス別

• 市場概要
• ベータラクタム
• マクロライド
• テトラサイクリン
• フルオロキノロン
• その他

抗生物質耐性の世界市場：病原体別

• 市場概要
• グラム陰性細菌
• グラム陽性菌

抗生物質耐性の世界市場：疾患別

• 市場概要
• 呼吸器感染症
• 尿路感染症
• 血流感染症
• その他

抗生物質耐性の世界市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • その他の欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2021年）
• 主要市場企業が採用した戦略
• 主要成功戦略
• 市場における最近の活動
• 主要企業の市場シェア（2021年）

主要企業プロファイル

• Pfizer Inc.（米国）
• Merck & Co., Inc.（米国）
• Johnson & Johnson（米国）
• Novartis AG（スイス）
• GlaxoSmithKline plc（英国）
• Achaogen Inc.（米国）
• Tetraphase Pharmaceuticals, Inc.（米国）
• Paratek Pharmaceuticals, Inc.（米国）
• Melinta Therapeutics, Inc.（米国）
• Cipla Ltd.（インド）
• Roche Holding AG（スイス）
• Sanofi（フランス）
• Eli Lilly and Company（米国）
• Bayer AG（ドイツ）
• Cubist Pharmaceuticals, Inc.（米国）
• Allergan plc（アイルランド）
• AstraZeneca plc（英国）
• Teva Pharmaceutical Industries Ltd.（イスラエル）
• Mylan N.V.（米国）
• Basilea Pharmaceutica Ltd.（スイス）

Global Antibiotic Resistance Market size was valued at USD 8.98 billion in 2022 and is poised to grow from USD 10.16 billion in 2023 to USD 27.39 billion by 2031, growing at a CAGR of 13.19% during the forecast period (2024-2031).

The global market for antibiotic resistance is witnessing significant expansion worldwide, driven by the escalating challenge posed by antibiotic-resistant bacteria. Our comprehensive report offers an in-depth analysis of the Antibiotic Resistance market's value chain, equipping manufacturers with insights to enhance their competitive positioning over the forecasted period. The pervasive issue of antibiotic resistance jeopardizes the efficacy of conventional treatments for infectious diseases, primarily attributed to the rampant misuse and overuse of antibiotics. Inadequate infection prevention measures within healthcare settings further exacerbate the spread of resistant strains, compounded by the alarming shortage of new antibiotics in development. Recognizing the urgency of this crisis, governments, healthcare entities, and pharmaceutical firms are increasingly rallying to combat antibiotic resistance through various means. Encouragement of public-private partnerships aims to stimulate antibiotic innovation, while the adoption of antibiotic stewardship programs gains momentum in optimizing antibiotic usage and curbing resistance. Concurrently, educational campaigns target healthcare practitioners and the general populace to improve prescribing practices and foster awareness about antibiotic resistance. Leveraging technological advancements such as genomics and proteomics holds promise in elucidating resistance mechanisms and devising novel therapeutic approaches. Emerging alternatives like phage therapy and immunotherapy offer potential solutions to counter antibiotic resistance. As the antibiotic resistance landscape presents both challenges and opportunities, concerted efforts are imperative to mitigate its escalating threat and safeguard effective bacterial infection treatment in the future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibiotic Resistance Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibiotic Resistance Market Segmental Analysis

The global antibiotic resistance market can be segmented based on drug-class, pathogen, disease type, and region. Based on drug class, the market can be divided into beta-lactams, macrolides, tetracyclines, fluoroquinolones, and others. Based on pathogens, the market can be categorized into gram-negative bacteria, gram-positive bacteria, and others. Based on disease types, the market can be categorized into respiratory infections, urinary tract infections, bloodstream infections, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Antibiotic Resistance Market

The escalating prevalence of infections caused by antibiotic-resistant bacteria underscores the urgency for the advancement of viable treatment modalities. With conventional antibiotics waning in efficacy, there arises a pressing need for novel antibiotics and alternative interventions to counteract resistant strains. This imperative propels intensive research and developmental endeavors, resulting in the identification of fresh pharmaceuticals and therapeutic strategies to tackle antibiotic resistance. Furthermore, heightened societal consciousness regarding the grave repercussions of antibiotic resistance has galvanized governmental bodies, healthcare institutions, and pharmaceutical enterprises to dedicate resources and undertake initiatives aimed at mitigating this challenge.

Restraints in the Global Antibiotic Resistance Market

The pipeline for developing novel antibiotics is notably constrained despite the escalating menace of antibiotic resistance. Crafting new antibiotics entails navigating a labyrinth of complexities and challenges, demanding substantial investments, time, and specialized knowledge. Yet, obstacles like exorbitant research and development expenses, regulatory hurdles, and minimal returns on investment have dampened antibiotic innovation. This scarcity of fresh antibiotic options severely impairs our capacity to combat antibiotic-resistant infections, emphasizing the pressing imperative for heightened initiatives and incentives to invigorate antibiotic development.

Market Trends of the Global Antibiotic Resistance Market

The increasing threat of antibiotic resistance has prompted a recognition that conventional antibiotic treatments alone may not effectively tackle the issue. Consequently, there's a movement towards investigating alternative strategies to combat bacterial infections. One prominent approach is the progress in phage therapy, where bacteriophages, viruses that infect and destroy bacteria, are utilized to target and eradicate antibiotic-resistant strains. This innovative method presents a promising avenue for addressing antibiotic resistance by precisely targeting harmful bacteria while preserving the beneficial microbiota.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Antibiotic Resistance Market by Drug-class

• Market Overview
• Beta-lactams
• macrolides
• tetracyclines
• fluoroquinolones
• others

Global Antibiotic Resistance Market by Pathogen

• Market Overview
• Gram-negative bacteria
• gram-positive bacteria

Global Antibiotic Resistance Market by Disease

• Market Overview
• Respiratory infections
• urinary tract infections
• bloodstream infections
• and others

Global Antibiotic Resistance Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Achaogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tetraphase Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Paratek Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Melinta Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cubist Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Basilea Pharmaceutica Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments